weight loss injections glp-1 FDA Approves First Generic Liraglutide for Semaglutide for Chronic Weight Management

For researchers exploring other metabolic compound categories, related overviews are available on MOTS-c research and peptide for longevity research

Dual GIP/GLP-1 agonists now represent the highest-revenue growth segment in the GLP-1 weight loss drug market at 18.4% CAGR , with tirzepatide generating USD 18.3 billion in 2025 revenue through Zepbound and Mounjaro surpassing Eli Lillys entire insulin franchise within two years of commercial launch

There are also strategic partnerships and a growing set of products that help drive market expansion

Minor complications such as mild soreness or redness at the injection site might happen, but generally fade away